Note 2 - Liquidity and Uncertainties	9 Months Ended
Sep. 30, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 — LIQUIDITY AND UNCERTAINTIES The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. As of September 30, 2021, the Company had an accumulated deficit of $106,582,501 and has incurred a net loss of approximately $2 million and $5.7 million for the three and nine month periods ending September 30, 2021, respectively. In April and June of 2020, the Company completed Common Stock Offerings generating net proceeds of approximately $4.6 million and $13.4 million, respectively (see Note 9). As of September 30, 2021, cash on hand was approximately $14.5 million, an increase of $0.3 million from December 31, 2020. Management believes the Company has sufficient liquidity to support operations beyond a year after the unaudited condensed consolidated financial statements issue date. The coronavirus (COVID-19) adversely impacted our operations and those of our distributors. As a result of the reduced hours and closings of dental offices throughout the country and the rest of the world, due to the continuing spread of COVID-19, revenues for the three and nine months ended September 30, 2020, were adversely affected. Business interruptions, including any interruptions resulting from COVID-19, could significantly disrupt our operations and could have a material adverse impact on our business during the remainder of 2021 and into 2022. In addition to our employees, we rely on (i) distributors, agents, and third-party logistics providers in connection with product sales and distribution and (ii) raw material and component suppliers in the U.S., Europe, and China. If we, or any of these entities encounter any disruptions to our or their respective operations or facilities, or if we or any of these third-party partners were to shut down for any reason, including by fire, natural disaster, such as a hurricane, tornado or severe storm, power outage, systems failure, labor dispute, pandemic or other public health crises, or other unforeseen disruption, then we or they may be prevented or delayed from effectively operating our or their business, respectively. In addition, it is uncertain as to what effect the continuing spread of COVID-19 (such as the Delta variant) will have on the commercialization efforts of our CompuFlo Epidural and CathCheck systems.. Such future developments could have a material adverse effect on our financial results and our ability to conduct business as expected.

Note 2 - Liquidity and Uncertainties

9 Months Ended

Sep. 30, 2021

Substantial Doubt about Going Concern [Text Block]

NOTE 2 — LIQUIDITY AND UNCERTAINTIES

The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. As of September 30, 2021, the Company had an accumulated deficit of $106,582,501 and has incurred a net loss of approximately $2 million and $5.7 million for the three and nine month periods ending September 30, 2021, respectively.

In April and June of 2020, the Company completed Common Stock Offerings generating net proceeds of approximately $4.6 million and $13.4 million, respectively (see Note 9). As of September 30, 2021, cash on hand was approximately $14.5 million, an increase of $0.3 million from December 31, 2020. Management believes the Company has sufficient liquidity to support operations beyond a year after the unaudited condensed consolidated financial statements issue date.

The coronavirus (COVID-19) adversely impacted our operations and those of our distributors. As a result of the reduced hours and closings of dental offices throughout the country and the rest of the world, due to the continuing spread of COVID-19, revenues for the three and nine months ended September 30, 2020, were adversely affected. Business interruptions, including any interruptions resulting from COVID-19, could significantly disrupt our operations and could have a material adverse impact on our business during the remainder of 2021 and into 2022.

In addition to our employees, we rely on (i) distributors, agents, and third-party logistics providers in connection with product sales and distribution and (ii) raw material and component suppliers in the U.S., Europe, and China. If we, or any of these entities encounter any disruptions to our or their respective operations or facilities, or if we or any of these third-party partners were to shut down for any reason, including by fire, natural disaster, such as a hurricane, tornado or severe storm, power outage, systems failure, labor dispute, pandemic or other public health crises, or other unforeseen disruption, then we or they may be prevented or delayed from effectively operating our or their business, respectively.

In addition, it is uncertain as to what effect the continuing spread of COVID-19 (such as the Delta variant) will have on the commercialization efforts of our CompuFlo Epidural and CathCheck systems.. Such future developments could have a material adverse effect on our financial results and our ability to conduct business as expected.